Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of First Rank Symptoms (FRS) on Schizophrenia

NCT ID: NCT03284138

Last Updated: 2025-09-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-08-03
• Study Completion Date: 2023-03-03

Brief Summary

First rank symptoms are core symptoms of schizophrenia. the investigators want to offer an integrative approach to better understanding of the mechanisms involved in the first rank symptoms and therefore, in schizophrenia, as well as the neuronal modulation mechanisms obtained by rTMS. It will be to pass a functional magnetic resonance imaging (fMRI) at rest for healthy volunteers, and for patients before and after rTMS modulation, to view brain structures activated in the resting state network, and in order to study

1. the difference of the resting-state network between healthy volunteers and people with schizophrenia,

2. if the response to rTMS boost can be predicted by resting-state network of patients before treatment and

3. if rTMS changes activations in the brain of patients. This will ultimately provide rTMS as a treatment of first rank symptoms.

Detailed Description

Schizophrenia is a common psychiatric disorder that affects approximately 1% of the general population. This disease can be described in three dimensions: disorganization, delusions and negative signs. The "first rank symptoms" (FRS) were first described by Kurt Schneider. These are core symptoms of schizophrenia that were combined to make pathognomonic signs of the disease and remain at the center of many classifications of the disease. These symptoms are voices or thoughts expressed aloud, voices who argue them, voices that comment on behavior or thoughts, delusional perceptions, experiences of body influences, thoughts influences, impulses from external influences, the will controlled by external forces, thoughts stolen by external forces or others, thoughts interferences by other thoughts, publication thoughts. These symptoms reveal difficulty in distinguishing self and other in action, thought or physical individual. Thus, the FRS are a gateway to agency disorder, disorder of the sense of body ownership and familiarity disorder.

Agency is the ability to distinguish ones own actions from those of others. The sense of body ownership is difficult to distinguish from the sense of agency. It is the knowledge that the arm (for example) which make this action is mine. A disorder of sense of body ownership may lead to the illusion of a phantom limb and it is very interesting to separate both mechanisms of body ownership and agency as wall as the networks involved in agency of those involved in the sense of body ownership. Familiarity is the feeling associated with the sight of someone close. Thus, in familiarity disorder, patient recognizes the facial features of relatives, but feels no sense of familiarity and attributes this to the replacement of the close by an impostor. Familiarity disorders can be understood through the 2-ways model of faces of processing in which the ventral pathway would be affected in the familiarity disorder. The ventral pathway involves a network which extends from the visual cortex to the superior temporal sulcus, the inferior parietal lobe and the cingulate gyrus to join the dorsal pathway in the hypothalamus.

In addition, agency studies imply the superior temporal sulcus and the inferior parietal lobule as regions involved in distinguishing self / others. Nowadays, remains a difficulty to clearly identify the different functions of the regions involved in agency.

Few neuroimaging studies can identify key areas of the sense of body ownership; in fact, protocols are difficult to adapt for use in a scanner. However, there are few studies that highlight, as was expected, extrastriatal body area as well as areas that may be involved in agency. Experiments have difficulty differentiating, as the investigators said, the sense of body ownership from agency, but the investigators have a validated tool, the rubber hand illusion, to differentiate sense of body ownership and agency. This tool has already been validated in healthy subjects , and was the subject of a study in our unit on patients with schizophrenia about to be published. In addition, several studies have shown that the performance at the rubber hand illusion task were modified by repeated Transcranial Magnetic Stimulation (rTMS) applied to the extrastriatal body area (EBA) or to the inferior parietal lobule (IPL) or to the temporo-parietal junction (TPJ).

Transcranial magnetic stimulation or TMS modulate cortical excitability without serious side effects when used at frequencies and intensities recommended in the literature. Low frequency rTMS is a recognized for treatment-resistant auditory hallucinations in schizophrenia. This is therefore an interesting therapeutic innovation that will benefit to residual symptoms, in adjunction to a well conducted medical treatment in schizophrenia.

To our knowledge, no study has been performed using rTMS as a treatment for FRS in schizophrenia. The investigators propose to evaluate the impact of treatment with low-frequency rTMS applied to the superior temporal sulcus in its posterior part (pSTS) on disorders of agency and familiarity. Indeed, it is well established that low-frequency rTMS (1 Hz) of the left TPJ was used to reduce auditory hallucinations in schizophrenia. On the same model, the investigators want to offer an innovative and integrative treatment of core symptoms of schizophrenia with the specificity of not focusing on a single symptom. The choice of pSTS allows also operating on the sense of body ownership inasmuch the TPJ is adjacent to the pSTS.

In addition, in order to have a more comprehensive study incorporating different aspects of the pathophysiology of schizophrenia, the investigators want to add a functional magnetic resonance imaging (fMRI) of resting-state. This would be to pass a fMRI for healthy volunteers. For people with schizophrenia, they will pass a fMRI before and after treatment for visualizing brain structures activated in the resting-state network, in order to study

1. the difference in resting-state circuitry between healthy volunteers and schizophrenia patients

2. whether the response to treatment with rTMS could be predicted by resting-state network of patients before treatment and

3. whether treatment with rTMS could modulate brain activations of patients.

Indeed, the resting-state network is the brain activity that occurs when a subject leaves his mind at rest without any particular task. Self-awareness is involved in this resting-state network. This network involves bilateral structures with the main nodes in medial prefrontal cortex, posterior cingulate cortex, precuneus and angular gyrus. People with schizophrenia exhibit connectivity anomalies in the resting-state network that are temporal connection anomalies. In acoustico-verbal hallucinations, people with schizophrenia have a resting-state network particularly active in the auditory cortex. Authors have proposed that this hyperactivity of the auditory cortex in the resting-state network would make patients more vulnerable to attribute external stimuli to them.

Similarly, it can be postulated that patients with FRS would have a hyperactivity of the resting-state network especially in the pSTS and the TPJ, which would lead to a difficulty in distinguishing oneself and others and thus, to FRS. Thus, the investigators hypothesize that patients with abnormal functional connectivity in the resting-state network (mainly in the pSTS and TPJ, which the investigators will then be boost in rTMS) will have a better response to treatment and that, after rTMS treatment, a change will be visible on neuronal activation of resting-state network in fMRI.

Conditions

Schizophrenia Patients With First Rank Symptoms

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

rTMS treatment

patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)

Group Type: ACTIVE_COMPARATOR

rTMS treatment

Intervention Type: DEVICE

patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)

Placebo treatment

patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled

Group Type: SHAM_COMPARATOR

placebo treatment

Intervention Type: DEVICE

patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled

Interventions

rTMS treatment

patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)

Intervention Type: DEVICE

placebo treatment

patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled

Intervention Type: DEVICE

Other Intervention Names

intervention; placebo

Eligibility Criteria

Inclusion Criteria

• Suffering from schizophrenia (according to DSM IV-TR)
• Presenting FRS at least once a day despite well-conducted antipsychotic treatment, objectified by FRS subscore of the SAPS (items 2, 3 and items 15-19) with at least two FRS listed > 1 of the corresponding item of the SAPS
• Being informed of the objectives and constraints of the study and signing the consent form or signing by the guardian
• Patient having had a preliminary clinical examination

Exclusion Criteria

• Left-lateralized
• Previously treated with rTMS in the previous 6 month,
• Contraindications of the rTMS practice: unstabilized epilepsy, presence of foreign eye metallic material, pacemaker, neurostimulator, cochlear implants and in general all medical equipment installed immovably, metal heart valve, vascular clips formerly located on cranial aneurysm
• Pregnancy or breastfeeding women
• hospitalization under constraint
• Subject already involved in another interventional clinical research evaluating schizophrenia treatment
• patient with severe drug use disorder (excluding coffee and tobacco) according to the DSM-5 criteria

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Aurely Ameller, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

Louis Mourier

Colombes, , France

Countries

France

Other Identifiers

P150906

Identifier Type: -

Identifier Source: org_study_id